rs2779249 — NOS2 Promoter -1026C/A

Every cell in your immune system carries a genetic volume knob for inducible nitric oxide synthase (iNOS), the enzyme that produces high-output bursts of nitric oxide during inflammatory responses. The rs2779249 variant sits in the NOS2 promoter region at position −1026 relative to the transcription start site — a regulatory element that controls how loudly the iNOS gene responds to inflammatory signals. Carrying the A allele at this position turns the volume up, and the functional data are clear: the A allele increases iNOS promoter transcriptional activity up to 5-fold compared to the C allele¹¹ 5-fold compared to the C allele
measured in luciferase reporter assays; the A allele alters binding of the transcription factor YY1 at this site, shifting the balance from transcriptional repression to activation.

The −1026C/A substitution sits within a transcription factor binding site in the NOS2 promoter. Functional studies using promoter-reporter constructs²² Functional studies using promoter-reporter constructs
Deng et al. Functional single nucleotide polymorphism -1026C/A of inducible nitric oxide synthase gene. Mol Cell Biochem. 2010 established that this position binds Yin Yang 1 (YY1), a transcription factor with repressor activity at this locus. The C allele supports dominant YY1 binding, which restrains NOS2 expression. The A allele disrupts YY1 occupancy and allows Nuclear Factor I (NFI) to bind preferentially — a factor that activates rather than represses transcription. The result is a constitutively more responsive NOS2 promoter: when pro-inflammatory signals arrive (NF-κB activation from infection, dietary triggers, adipokines, or cellular stress), iNOS mRNA levels rise higher and faster in A-allele carriers.

Critically, this is a transcriptional volume effect, not a protein function effect. Unlike rs2297518 (the S608L coding variant in the same gene that increases per-molecule iNOS enzymatic activity), rs2779249 controls how many iNOS molecules are made in the first place. The two variants therefore operate at different levels of the same output system — and when co-inherited, their effects on total nitric oxide production are additive.

The downstream consequences of chronically elevated iNOS output are the same regardless of which NOS2 variant drives it: excess NO reacts with superoxide (O₂⁻) to form peroxynitrite (ONOO⁻)³³ peroxynitrite (ONOO⁻)
a potent reactive nitrogen species that nitrates proteins, oxidizes lipids, and damages mitochondrial DNA — far more destructive than either NO or superoxide alone. Peroxynitrite-mediated damage accumulates as 3-nitrotyrosine (3-NT)⁴⁴ 3-nitrotyrosine (3-NT)
a stable biomarker of in vivo nitrosative stress, elevated in aging, cardiovascular disease, neurodegeneration, and metabolic syndrome, and activates NF-κB in a positive feedback loop that sustains inflammatory gene expression — a molecular description of inflammaging⁵⁵ inflammaging
the chronic, low-grade, sterile inflammation that underlies most major age-related diseases.

The most direct evidence for rs2779249's functional importance comes from the 2009 mechanistic study (PMID 19402223) that demonstrated the 5-fold promoter activity difference between alleles and identified the YY1/NFI transcription factor switch as the molecular basis. This level of functional characterization — allele-specific promoter activity measured directly in human cells — places rs2779249 among the better-characterized regulatory SNPs in the NOS2 locus.

For clinical associations, the TAMRISK study⁶⁶ TAMRISK study
Muranen L et al. Functional Inducible Nitric Oxide Synthase Gene Variants Associate With Hypertension: A Case-Control Study in a Finnish Population. Medicine (Baltimore). 2015 is the strongest dataset. Among 320 hypertensive cases and 439 normotensive controls aged 50, A-allele carriers had OR = 1.47 (95% CI 1.08–2.01, p = 0.015) for hypertension at age 50. Prospective 15-year follow-up data from prior cross-sections (ages 35, 40, 45) showed even larger effects earlier in life — at age 35, OR = 3.83 (95% CI 1.20–12.27, p = 0.024) — suggesting the promoter variant's effect on vascular risk is visible decades before clinical hypertension typically manifests. The critical haplotype finding: when rs2779249-A and rs2297518-A were co-inherited as haplotype H3 (present in ~20% of the study population), the hypertension OR rose to 2.01 (95% CI 1.29–3.12, p = 0.002), larger than either variant alone.

An independent Han Chinese replication⁷⁷ An independent Han Chinese replication
Relationship between inducible NOS single-nucleotide polymorphisms and hypertension in Han Chinese. Herz. 2017 in 1,172 hypertensive and 1,172 control subjects confirmed the association: rs2779249 A allele was associated with hypertension with OR = 1.27 (additive model), 1.31 (dominant), and 1.68 (recessive). The replication in a second major population substantially strengthens the confidence in the finding.

An Eastern Siberian cohort study⁸⁸ An Eastern Siberian cohort study
Alyabyeva et al. Association of SNPs Rs2779249 and Rs2297518 of NOS2 with tension-type headache and hypertension overlap syndrome. Genes (Basel). 2023 of 91 participants found the A allele frequency elevated from 14.5% in healthy controls to 35% in overlap syndrome patients (OR 3.17 for overlap, OR 2.94 for arterial hypertension alone), confirming the vascular signal in a further population.

Beyond vascular disease, a 2023 bladder cancer case-control study⁹⁹ a 2023 bladder cancer case-control study
Wróbel-Bednarz K et al. The role of SOD2 and NOS2 genes in bladder cancer pathophysiology. Sci Rep. 2023 found a sex-differentiated association: CA heterozygotes had reduced bladder cancer risk overall, while CC homozygotes (who lack the A allele entirely) had increased bladder cancer risk specifically in women — a paradox that may reflect tissue-specific roles of NOS2 expression in tumor immune surveillance versus nitrosative DNA damage, or differential iNOS/NO effects in tumor initiation versus progression.

Because rs2779249 increases iNOS transcriptional output, the most impactful interventions are those that reduce NF-κB-driven iNOS induction signals — the upstream triggers that the amplified promoter responds to. Every reduction in the inflammatory signals reaching the NOS2 promoter translates directly to less iNOS mRNA, fewer iNOS protein molecules, and lower peroxynitrite output. The same dietary, antioxidant, and monitoring strategies that apply to rs2297518 carriers apply here — but with the emphasis shifted toward reducing induction stimuli rather than countering enzymatic output directly.

Key modifiable inducers of NOS2 transcription include: dietary saturated fat and advanced glycation end products (AGEs) that activate NF-κB through TLR4; visceral adipose tissue cytokines (TNF-α, IL-6, IL-1β); chronic low-grade infections (periodontal, gut dysbiosis, respiratory); and sleep restriction, which activates NF-κB through hypoxia-inducible factor signaling. Each of these inputs drives NF-κB → NOS2 transcription, and in A-allele carriers, the amplified promoter magnifies the response to each trigger.

Blood pressure monitoring is the highest-yield clinical action, given the consistent hypertension signal across Finnish, Chinese, and Siberian cohorts.

rs2779249 and rs2297518 form the NOS2 haplotype H3 (both A alleles co-inherited) that is the most clinically relevant genetic unit in this locus. The TAMRISK study documented¹⁰¹⁰ The TAMRISK study documented
Muranen L et al. 2015 that H3 carries OR = 2.01 for hypertension, larger than either variant alone — consistent with the additive model in which promoter-driven increased transcription (rs2779249-A) combines with per-molecule increased enzymatic activity (rs2297518-A) to produce maximal total NO output. Carriers of both A alleles should receive the most intensive monitoring and intervention recommendations. An Italian migraine study¹¹¹¹ An Italian migraine study
Esposito M et al. Inducible nitric oxide synthase haplotype associated with migraine and aura. Mol Cell Biochem. 2012 found the same H3 haplotype more prevalent in migraine with aura (19% vs 10% in controls, p = 0.0245), adding a neurological dimension to the haplotype's effect.

The AKT1 variant rs3803304¹²¹² AKT1 variant rs3803304
intronic AKT1 variant associated with reduced longevity in centenarian studies intersects with the NOS2 promoter through a distinct mechanism: AKT1 phosphorylates and stabilizes NOS2 mRNA, increasing iNOS protein expression from a given level of mRNA. Carriers of risk alleles in both rs2779249 (increased transcription) and rs3803304 (increased mRNA stability) would theoretically experience synergistic iNOS protein elevation, though this combination has not been directly tested in human cohorts.